Insmed Inc (NASDAQ:INSM) Sentiment Dropped in 2018 Q3 to 0.82

Insmed Incorporated (NASDAQ:INSM) Corporate Logo

“Big money” Positions

In 2018 Q3 Insmed Inc (NASDAQ:INSM) big money sentiment decreased to 0.82, revealed SEC filings. That’s down -0.38, from 2018Q2’s 1.2. 46 institutional investors started new or increased positions, while 56 sold and trimmed positions in Insmed Inc so the sentiment worsened. These funds own 76.71 million shares, that’s down from 78.27 million shares in 2018Q2. Funds holding Insmed Inc in top 10 was flat from 1 to 1 for the same number . 21 Investors Sold All; 35 Reduced Holdings; 25 increased holdings while 21 institutional investors bought holdings.

Significant Insmed Inc Shareholders

As of 2018 Q3 Foresite Capital Management Ii Llc has 7.24% invested in Insmed Inc. Insmed Inc’s shareholder Rock Springs Capital Management Lp owns 890,000 shares as of 2018 Q3. Further, Emerald Advisers Inc Pa reported 791,474 shares in Insmed Inc equivalent to 0.59% of its US long equity exposure. Emerald Mutual Fund Advisers Trust revealed 845,858 shares position in Insmed Inc. The Indiana-based fund University Of Notre Dame Du Lac holds 132,220 shares or 0.5% of their US long equity exposure.

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases.The firm is worth $2.01 billion. The companyÂ’s lead product candidate is ARIKAYCE or liposomal amikacin for inhalation, a formulation of amikacin that is in late-stage clinical development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by Mycobacterium avium complex.Last it reported negative earnings. It is also developing INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1, which has completed a Phase I clinical study for activating neutrophil serine proteases that are implicated in the pathology of chronic inflammatory lung diseases, such as non-cystic fibrosis bronchiectasis; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug, which has completed a Phase I clinical study for treating rare pulmonary disorders, including pulmonary arterial hypertension.

The stock increased 0.19% or $0.05 during the last trading session, hitting $26.02.Insmed Incorporated has volume of 573,921 shares. Since February 14, 2018 INSM has declined 42.91% and is downtrending. The stock underperformed the S&P 500 by 42.91%.

On February, 22 is anticipated Insmed Incorporated (NASDAQ:INSM)’s earnings report, Faxor reports. The EPS diference is $0.30 or 35.29 % down from last years number. Previous year: $-0.85; Analysts forcast: $-1.15. 0.88 % negative EPS growth is what analysts predict. $-1.14 EPS was published for last quarter.

Qs Invsts reported 69,831 shs stake. Cubist Systematic Strategies Limited Co stated it has 0.01% in Insmed Incorporated (NASDAQ:INSM). Franklin Street Inc Nc reported 0.04% of its capital in Insmed Incorporated (NASDAQ:INSM). The Massachusetts-based Rhumbline Advisers has invested 0% in Insmed Incorporated (NASDAQ:INSM). 126,700 were reported by California Pub Employees Retirement. Credit Suisse Ag has 41,528 shs for 0% of their capital. Botty Invsts Ltd Liability Corporation reported 0.01% in Insmed Incorporated (NASDAQ:INSM). The New York-based Goldman Sachs Gru has invested 0% in Insmed Incorporated (NASDAQ:INSM). California State Teachers Retirement Sys reported 117,158 shs stake. National Bank Of America Corp De invested 0% in Insmed Incorporated (NASDAQ:INSM). Moreover, State Board Of Administration Of Florida Retirement Sys has 0% invested in Insmed Incorporated (NASDAQ:INSM) for 38,450 shs. Aqr Cap Limited Liability Company holds 99,003 shs or 0% of its capital. Ubs Asset Mgmt Americas Inc, Illinois-based fund reported 49,823 shs. Tower Rech Cap Lc (Trc) has invested 0% in Insmed Incorporated (NASDAQ:INSM). Jefferies Gp Limited Liability Com stated it has 0.01% of its capital in Insmed Incorporated (NASDAQ:INSM).

Insmed Incorporated had 2 insider sales and 4 insider purchases since November 1, 2018. This’s net activity of $610,461. 16,085 shs were bought by ENGELSEN STEINAR J, worth $253,993. SHAROKY MELVIN MD bought 20,000 shs worth $320,211. 15,700 shs were bought by Lewis William, worth $249,600. Adsett Roger bought 3,000 shs worth $47,907.

Insmed Incorporated (NASDAQ:INSM) Ratings Coverage

Total analysts of 5 have positions in Insmed (NASDAQ:INSM) as follows: 4 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 80%. Since October 1, 2018 according to StockzIntelligence Inc Insmed has 5 analyst reports. On Monday, October 1 Morgan Stanley maintained Insmed Incorporated (NASDAQ:INSM) with “Overweight” rating. On Thursday, January 17 the rating was upgraded by Goldman Sachs to “Buy”. On Monday, October 1 the rating was maintained by Credit Suisse with “Outperform”. On Tuesday, December 4 the firm has “Neutral” rating by Citigroup given.

For more Insmed Incorporated (NASDAQ:INSM) news posted recently go to: Seekingalpha.com, Nasdaq.com, Seekingalpha.com, Benzinga.com or Seekingalpha.com. The titles are as follows: “Insmed nabs new ALIS patent in Japan – Seeking Alpha” posted on October 04, 2018, “Options Traders Expect Huge Moves in Insmed (INSM) Stock – Nasdaq” on January 25, 2019, “Insmed: Will ALIS Procure A Positive Regulatory Outcome? – Seeking Alpha” with a publish date: July 30, 2018, “34 Stocks Moving In Thursday’s Mid-Day Session – Benzinga” and the last “FDA Ad Com backs Insmed’s ALIS for subpopulation of patients with NTM lung disease caused by MAC – Seeking Alpha” with publication date: August 08, 2018.

Insmed Incorporated (NASDAQ:INSM) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.